Market Research Logo

Global Renal Biomarkers Market – Growth, Trends and Forecasts (2017 - 2022)

Global Renal Biomarkers Market – Growth, Trends and Forecasts (2017 - 2022)

The global renal biomarker market is estimated to be USD XX billion in 2017 and is expected to reach USD XX billion by 2022, registering a healthy CAGR of XX%, during 2017-2022 (forecast period).

Kidney diseases are among the major causes of deaths, worldwide. With the increasing incidences of chronic kidney diseases, especially, among the geriatric population, the need for novel biomarkers for early detection of the disease is increasing. Biomarkers are medical signs or objective indications of a medical state observed from outside the patient, measured accurately and reproducibly. At present, serum creatinine, which is used to measure the glomerular filtration rate (GFR), is the most common marker for renal function.

The market growth is majorly driven by the increasing prevalence of various kidney-related diseases. The high prevalence of diabetes and high blood pressure are also accelerating the market, as they can lead to renal diseases. Other prominent growth factors include rapid technological advances in genetics, which is leading to the discovery of novel biomarkers, and the increasing need to personalize medicine for patients, to decrease treatment costs. However, the market is restrained due to issues with the regulatory and reimbursement policies.

The global renal biomarkers market is segmented into biomarker type, diagnostic technique, type of end-user and geography. Based on the type of biomarker, the market is segmented into functional biomarkers, up-regulated proteins and other types. The functional biomarkers segment is further segmented into serum creatinine, serum cystatin c, urine albumin; the up-regulated proteins segment is further divided into neutrophil gelatinase-associated lipocalin, kidney injury molecule – 1 and interleukin 18. Further, based on the diagnostic technique, the market is segmented into enzyme linked immunosorbent assay, particle-enhanced turbid metric immunoassay, colorimetric assay and others. The market is segmented, by the end-user type, into diagnostic labs, outpatient clinics, research centers & hospitals.

Based on geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa and South America. These regions are further segmented into countries in their respective regions.

Some of the major players in this market are –

Abbott Laboratories

Alere Inc.

Siemens Healthcare

Roche Diagnostics Corporation

Beckman Coulter Inc.

Randox Laboratories Ltd.

Key Deliverables

Market analysis, with region-specific assessments and competition analysis on a global and regional scale.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenario, growing prospective opportunities, and identification of key companies that can influence the market.

Extensively researched competitive landscape section with profiles of major companies, along with their market share.

Identification and analysis of the macro and micro factors that affect the market on both, global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

A wide-range of knowledge and insights about the major players in the industry and the key strategies adopted by them to sustain and grow in the studied market

Insights on the major countries/regions where the industry is growing, and identify the regions that are still untapped.


1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
5.1 Porter's Five-Force Analysis
5.1.1 Threat of New Entrant
5.1.2 Internal Rivalry
5.1.3 Buyer Bargaining Power
5.1.4 Supplier Bargaining Power
5.1.5 Threat of Substitutes
6. Market Dynamics
6.1 Market Drivers
6.1.1 Rising Prevalence of Various Kidney Related Diseases
6.1.2 The High Prevalence of Diabetes and High Blood Pressure as they are the Leading Cause of Renal Diseases
6.1.3 Rapid Technological Advances in the Field of Genetics
6.2 Market Restraints
6.2.1 Issues Related to Regulatory and Reimbursement Systems
6.3 Market Opportunities
6.4 Market Challenges
7. Market Segmentation by Biomarker Type
7.1 Functional Biomarker
7.1.1 Serum Creatinine
7.1.2 Serum Cystatin C
7.1.3 Urine Albumin
7.2 Up-Regulated Proteins
7.2.1 Neutrophil Gelatinase-Associated Lipocalin
7.2.2 Kidney Injury Molecule-1
7.2.3 Interleukin-18
7.3 Others
8. Market Segmentation by Diagnostic Technique
8.1 Enzyme Linked Immunosorbent Assay (ELISA)
8.2 Particle-Enhanced Turbidimetric Immunoassay (PETIA)
8.3 Colorimetric Assay
8.4 Chemiluminescent Enzyme Immunoassay (CLIA)
8.5 Liquid Chromatography-Mass Spectrometry (LS-MS)
9. Market Segmentation By End User
9.1 Diagnostic Labs
9.2 Outpatient Clinics
9.3 Research Centers
9.4 Hospitals
10. Market Segmentation by geography
10.1 North America
10.1.1 United States
10.1.2 Canada
10.1.3 Mexico
10.2 Europe
10.2.1 United Kigdom
10.2.2 Spain
10.2.3 Italy
10.2.4 France
10.2.5 Germany
10.2.6 Rest of Europe
10.3 Asia-Pacific
10.3.1 India
10.3.2 China
10.3.3 Japan
10.3.4 Australia
10.3.5 Rest of APAC
10.4 South America
10.4.1 Brazil
10.4.2 Argentina
10.4.3 Rest of South America
11. Competitive Landscape
11.1 Mergers and Acquisitions
11.2 Partnerships, Collaborations and Agreements
11.3 New Product Launches
12. Company Profiles
12.1 Beckman Coulter, Inc.
12.2 Thermo Fisher Scientific, Inc.
12.3 Abbott Laboratories
12.4 BIOPORTO A/S
12.5 Astute Medical, Inc.
12.6 Randox Laboratories Ltd.
12.7 Siemens Healthcare Diagnostics, Inc.
12.8 Alere, Inc.
12.9 F. Hoffmann-La Roche AG
12.10 BioMérieux SA

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report